A new treatment regimen for hepatitis C, the most common cause of
liver cancer and transplantation, has produced results that will
transform treatment protocols for transplant patients, according to
research published online today in the New England Journal of Medicine.
The investigational three-drug regimen, which
produced hepatitis C cure rates of 97 percent, is an oral
interferon-free therapy. Previously, the typical treatment for hepatitis
C after a liver transplant was an interferon-based therapy, usually
given for 48 weeks. It had a much lower response rate, had a risk of
organ rejection and was poorly tolerated because of the
immunosuppressants required to prevent rejection. The new oral
regimen—ABT-450, ombitasvir and dasabuvir (with or without
ribavirin)—produces significantly fewer side effects and is prescribed
for 24 weeks.
First author Paul Kwo, M.D., professor of medicine at the Indiana
University School of Medicine, called the results of the international
clinical study a "landmark achievement."
Labels: Abbvie 3D, post-transplant SVR